AbCellera Biologics Inc.
NASDAQ:ABCLBiotechnology
Healthcare
$10.47 -0.28%
-$0.02 today
- Market cap
- $3.42B
- Beta
- 1.20
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.47
52W Low $2.75High $6.79
Volume 2.48M
Average 6.37M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$131.29M
FY 2025 · Annual
Investing Cash Flow
$87.75M
FY 2025 · Annual
-27.7% YoYFinancing Cash Flow
$14.08M
FY 2025 · Annual
+10.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 153.46M | 158.52M | (146.4M) | (162.86M) | (146.41M) |
| Depreciation & Amortization | 17.25M | 33.1M | 30.89M | 97M | 28.82M |
| Deferred Income Tax | (2.02M) | (2.11M) | 1.96M | 0 | 0 |
| Stock-Based Compensation | 30.65M | 49.48M | 64.18M | 67.58M | 55.79M |
| Change in Working Capital | 41.67M | 29.83M | 13.23M | (25.84M) | (70.69M) |
| Accounts Receivables | 22.48M | (22.72M) | (45.93M) | (75.12M) | (55.62M) |
| Inventory | 0 | 0 | 18.25M | 0 | 0 |
| Accounts Payables | 1.4M | 1.07M | (15.1M) | 10.64M | 3.46M |
| Other Working Capital | 17.79M | 51.47M | 56.01M | 38.64M | (18.53M) |
| Other Non-Cash Items | 3.57M | 8.55M | (7.74M) | (84.44M) | 1.2M |
| Operating Cash Flow | 244.58M | 277.36M | (43.88M) | (108.56M) | (131.3M) |
| Capital Expenditures | (58.45M) | (72.66M) | (77.51M) | (78.4M) | (42.77M) |
| Acquisitions (Net) | (11.46M) | (25.68M) | (13.69M) | (19.63M) | (7.14M) |
| Purchases of Investments | (322.57M) | (781.35M) | (1.07B) | (765.09M) | (453.14M) |
| Sales of Investments | 27.61M | 510.63M | 910.94M | 948.81M | 506.07M |
| Other Investing Activities | 32.62M | 16.43M | 25.31M | 35.71M | 84.72M |
| Investing Cash Flow | (332.25M) | (352.63M) | (221.11M) | 121.41M | 87.75M |
| Debt Repayment | (951K) | 2.76M | 11.59M | 13.5M | 0 |
| Common Stock Issued | 4.62M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.55M) | (4.38M) | (1.23M) | (729K) | 14.08M |
| Financing Cash Flow | (3.89M) | (1.63M) | 10.36M | 12.77M | 14.08M |
| Effect of Forex Changes | (1.43M) | (9.6M) | 589K | (2.62M) | 1.1M |
| Net Change in Cash | (92.97M) | (86.49M) | (254.04M) | 23.01M | (28.37M) |
| Free Cash Flow | 186.13M | 204.7M | (121.38M) | (186.95M) | (174.07M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$146.4M
+ D&A$28.8M
+ Stock-Based Comp$55.8M
+ Deferred Tax$0
- Working Capital-$70.7M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$131.3M
- Capex-$42.8M
= Free Cash Flow-$174.1M
Analysis
FY2025 free cash flow is -$174.1M. FCF conversion is 118.9% of net income. Operating cash flow was -$131.3M, with capex of -$42.8M. The largest bridge item is Working Capital at -$70.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 8-K | Current report | Nov 9, 2026 |
Does ABCL generate free cash flow?
AbCellera Biologics Inc. (ABCL) generated -$174.07M of free cash flow in fiscal 2025.
How much operating cash flow does ABCL produce?
Operating cash flow was -$131.29M, before capital expenditures of $42.77M.
Continue the stock analysis
Jump to another research area for this company.